Skip to main content
Back
ALPMF logo

Astellas Pharma Inc.

Data quality: 100%
ALPMF
OTC Healthcare Drug Manufacturers - General
$16.15
▼ $0.10 (-0.62%)
Mkt Cap: 28.93B
Also listed as ALPMY OTC
Day Range
$14.25 $16.15
52-Week Range
$8.40 $17.39
Volume
100
50D / 200D Avg
$15.05 / $12.11
Prev Close
$16.25

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.6 0.4
P/B 0.0 2.9
ROE % 3.3 3.8
Net Margin % 2.7 3.9
Rev Growth 5Y % 11.2 10.0
D/E 0.6 0.2

Key Takeaways

Revenue grew 11.23% annually over 5 years — strong growth
Earnings grew 197.72% over the past year
ROE of 3.26% is below average
Generating 137.18B in free cash flow
P/E of 0.57 — trading at a low valuation
PEG of 0.26 suggests growth is underpriced

Growth

Revenue Growth (5Y)
11.23%
Revenue (1Y)19.25%
Earnings (1Y)197.72%
FCF Growth (3Y)-24.27%

Quality

Return on Equity
3.26%
ROIC1.31%
Net Margin2.65%
Op. Margin2.15%

Safety

Debt / Equity
0.55
Current Ratio1.13
Interest Coverage2.32

Valuation

P/E Ratio
0.57
P/B Ratio0.02
EV/EBITDA16.37
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19.25% Revenue Growth (3Y) 12.22%
Earnings Growth (1Y) 197.72% Earnings Growth (3Y) -28.30%
Revenue Growth (5Y) 11.23% Earnings Growth (5Y) -19.46%
Profitability
Revenue (TTM) 1.91T Net Income (TTM) 50.75B
ROE 3.26% ROA 1.52%
Gross Margin 81.74% Operating Margin 2.15%
Net Margin 2.65% Free Cash Flow (TTM) 137.18B
ROIC 1.31% FCF Growth (3Y) -24.27%
Safety
Debt / Equity 0.55 Current Ratio 1.13
Interest Coverage 2.32 Dividend Yield 0.05%
Valuation
P/E Ratio 0.57 P/B Ratio 0.02
P/S Ratio 0.02 PEG Ratio 0.26
EV/EBITDA 16.37 Dividend Yield 0.05%
Market Cap 28.93B Enterprise Value 671.99B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.91T 1.60T 1.52T 1.30T 1.25T
Net Income 50.75B 17.05B 98.71B 124.09B 120.59B
EPS (Diluted) 28.24 9.47 54.09 67.05 64.90
Gross Profit 1.56T 1.31T 1.23T 1.04T 1.00T
Operating Income 41.04B 25.52B 133.03B 220.02B 136.05B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3.34T 3.57T 2.46T 2.33T 2.27T
Total Liabilities 1.83T 1.97T 948.56B 872.09B 887.51B
Shareholders' Equity 1.51T 1.60T 1.51T 1.46T 1.39T
Total Debt 831.43B 1.01T 200.01B 212.74B 278.26B
Cash & Equivalents 188.37B 335.69B 376.84B 315.99B 326.13B
Current Assets 1.20T 1.19T 1.05T 923.35B 872.59B
Current Liabilities 1.06T 1.29T 726.03B 687.41B 592.37B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#31 of 1024
80
Growth Price/Sales Ratio Focus (Ken Fisher)
#477 of 616
18

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026